Identifying these RB1 mutations is relevant to treatment, because tumors harboring inactivation of RB1 are unlikely to respond to CDK4/6 inhibitors, which have been developed and are being investigated as glioma therapy48,50. Here, RB1 is linked to central nervous system cancer.